# Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

> **NCT02825212** · PHASE2,PHASE3 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 10 (actual)

## Conditions studied

- Hepatitis C
- Cryoglobulinemia

## Interventions

- **DRUG:** Harvoni
- **DRUG:** Epclusa

## Key facts

- **NCT ID:** NCT02825212
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2019-07-19
- **Final completion:** 2019-07-19
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02825212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02825212, "Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02825212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*